[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

21d ago

PremiumPress Releases

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

26d ago

PremiumPress Releases

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

28d ago

$[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study$

PremiumPress Releases

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

30d ago

PremiumPress Releases

Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer’s disease diagnosis

1M ago

PremiumPress Releases

Roche receives FDA approval for the first molecular test to screen for malaria in blood donors

2M ago

PremiumPress Releases

Roche Annual General Meeting 2024

2M ago

More RHHVF News >

RHO5 News on the Web

2024-04-24

'Greater tailwind than the U.S.': Morningstar strategist likes these 7 European stocks

CNBC

Neutral

2024-04-24

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Day One Biopharmaceuticals (DAWN) and Roche Holding AG (OtherRHHVF)

TipRanks News

Bullish

2024-04-24

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Danaher (DHR) and Roche Holding AG (OtherRHHVF)

TipRanks News

Neutral

2024-04-24

Swiss pharma giant Roche's first-quarter sales edge higher as its emerges from post-Covid-19 slump

CNBC

Neutral

2024-04-19

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Yahoo Finance

Neutral

2024-04-18

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

Yahoo Finance

Neutral

2024-04-18

UBS Sticks to Its Hold Rating for Roche Holding AG (RHHVF)

TipRanks News

Neutral

2024-04-17

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Yahoo Finance

Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score

Media Buzz

This Week0 articles

Weekly Average0 articles

News Sentiment

Currently, no data available

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:RHO5’s Media Buzz Sentiment?

Currently, no data Available

What is DE:RHO5’s weekly average amount of articles?

Currently, no data Available

What is DE:RHO5’s News Sentiment?

Currently, no data Available

Healthcare Stocks that are Trending in the News

MTDMettler-Toledo

SYRESpyre Therapeutics

CRNXCrinetics Pharmaceuticals

HAEHaemonetics

LEGNLegend Biotech

Showing the stocks with the most bullish news sentiment over the past week

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing